Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to pilot test CTNow, an educational program designed to improve access and referrals to cancer clinical trials for patients and oncology providers in rural areas. The program focuses on increasing awareness and understanding of clinical trials through patient and provider education and teleconference resources. The study is sponsored by the University of Hawaii and targets individuals involved in cancer care within rural communities. The study includes two main interventions a patient education program and a provider education program. Patients receive a multimedia educational series lasting about 30 minutes, covering topics such as what clinical trials are, their types and phases, benefits and drawbacks, costs, and how to join. Providers participate in three individual teleconference sessions tailored to their background, covering clinical trial infrastructure in Hawaii, available trials, and how to get involved, with follow-up sessions scheduled 4 to 6 months later. Participants will be evaluated over 18 months to assess changes in patients awareness and knowledge of clinical trials. Assessments include educational video viewing and provider workshops conducted via teleconference. Patients must be residents of specific Hawaiian counties and able to understand English. The study includes tracking of patient and provider engagement, with no masking or randomization involved. Participation is expected to enhance understanding of clinical trials within these rural communities.
Actively Recruiting
Researchers are evaluating the side effects and effectiveness of adding inotuzumab ozogamicin to frontline chemotherapy for young adults aged 18 to 39 with newly diagnosed B acute lymphoblastic leukemia, a type of blood cancer. Inotuzumab ozogamicin is a targeted therapy that delivers a chemotherapy drug directly to cancer cells. This phase III trial aims to confirm the safety and improve event-free survival compared to standard pediatric-inspired chemotherapy. Participants receive a combination of chemotherapy drugs in several treatment courses, including remission induction, remission consolidation, interim maintenance, delayed intensification, and maintenance therapy. Those in the experimental group receive inotuzumab ozogamicin intravenously on specific days alongside chemotherapy, with additional treatments like blinatumomab given if minimal residual disease is detected. Procedures such as bone marrow biopsies and imaging are performed throughout. Participants will be closely monitored through blood tests, bone marrow samples, imaging scans, and symptom assessments. Researchers will measure outcomes like event-free survival, disease-free survival, overall survival, response rates, and adverse events over several years. After treatment, participants are followed regularly for up to 10 years to assess long-term effects and survival.